Teva Pharmaceutical Industries Ltd (TEVA) to Post Q1 2018 Earnings of $0.63 Per Share, Leerink Swann Forecasts

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Leerink Swann boosted their Q1 2018 EPS estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, April 16th. Leerink Swann analyst A. Fadia now anticipates that the company will post earnings per share of $0.63 for the quarter, up from their previous estimate of $0.61. Leerink Swann currently has a “Underperform” rating and a $16.00 target price on the stock. Leerink Swann also issued estimates for Teva Pharmaceutical Industries’ Q2 2018 earnings at $0.59 EPS, Q3 2018 earnings at $0.55 EPS, Q4 2018 earnings at $0.50 EPS, FY2018 earnings at $2.24 EPS, FY2019 earnings at $2.51 EPS, FY2020 earnings at $2.34 EPS and FY2022 earnings at $2.78 EPS.

How to Become a New Pot Stock Millionaire

A number of other research analysts have also issued reports on TEVA. Credit Suisse Group set a $23.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, April 4th. Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a research report on Monday, March 12th. BTIG Research lowered Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price target for the company. in a research report on Friday, February 2nd. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Finally, ValuEngine lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Eleven equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $19.67.

Shares of TEVA stock opened at $17.92 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $33.82. The firm has a market cap of $18,364.80, a price-to-earnings ratio of 4.56, a price-to-earnings-growth ratio of 1.57 and a beta of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. The business’s revenue for the quarter was down 15.9% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. raised its position in shares of Teva Pharmaceutical Industries by 16.9% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 45,983 shares of the company’s stock worth $871,000 after purchasing an additional 6,642 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $243,000. Meitav Dash Investments Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $5,017,000. MetLife Investment Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $1,335,000. Finally, Hoylecohen LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $954,000. 58.22% of the stock is currently owned by institutional investors.

In other news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the sale, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 10,734 shares of company stock worth $204,795 over the last ninety days. 7.10% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/19/teva-pharmaceutical-industries-ltd-teva-to-post-q1-2018-earnings-of-0-63-per-share-leerink-swann-forecasts.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply